Despite the rapid development of emerging therapies for SLE, glucocorticoids remain an important component of disease management. "How well do our current corticosteroid prescribing habits align with current treatment guidelines?" On day 1 of the SLE poster sessions, several abstracts have demonstrated notable trends in glucocorticoid utilization.
All News
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and potential future targeted therapies. This review builds on other important reports on CPPD.
Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients who will require chronic glucocorticoids.
Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.
